Hussein A. Tawbi
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers 83
- CAR-T cell therapy research 52
- Cutaneous Melanoma Detection and Management 20
- Immunology top 2%
- Immunotherapy and Immune Responses 25
-
- Brain Metastases and Treatment 38
- Lung Cancer Treatments and Mutations 10
- Genetics top 5%
- Glioma Diagnosis and Treatment 14
- Cancer Research top 10%
-
- Melanoma and MAPK Pathways 51
- Co-authors
- John M. KirkwoodAhmad A. TarhiniF. Stephen HodiCindy SanderEvan J. LipsonMichael A. DaviesKristen N. GanjooMargaret von Mehren
- Journals
- Proceedings of the National Academy of Sciences (1 paper)Nature Medicine (1 paper)Journal of Clinical Oncology (35 papers)
- Partner nations
- United StatesAustraliaGermany
In The Last Decade
Hussein A. Tawbi
143 papers receiving 4.3k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Oncology 3.0k
- Immunology 1.3k
- Pulmonary and Respiratory Medicine 1.4k
- Genetics 291
- Cancer Research 303
Countries citing papers authored by Hussein A. Tawbi
This map shows the geographic impact of Hussein A. Tawbi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hussein A. Tawbi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hussein A. Tawbi more than expected).
Fields of papers citing papers by Hussein A. Tawbi
This network shows the impact of papers produced by Hussein A. Tawbi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hussein A. Tawbi. The network helps show where Hussein A. Tawbi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hussein A. Tawbi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 17 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 1 | |
| 7 | 2023 | 7 | |
| 8 | 2023 | 3 | |
| 9 | 2023 | 3 | |
| 10 | 2023 | 13 | |
| 11 | 2023 | 7 | |
| 12 | 2022 | 30 | |
| 13 | 2021 | 13 | |
| 14 | 2021 | 1 | |
| 15 | 2020 | 52 | |
| 16 | 2020 | 2 | |
| 17 | 2019 | 33 | |
| 18 | Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trialbreakdown → | 2015 | 576 |
| 19 | 2014 | 85 | |
| 20 | 2013 | 175 |
About Hussein A. Tawbi
Hussein A. Tawbi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics, having authored 152 papers that have together received 4.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (83 papers), CAR-T cell therapy research (52 papers), Melanoma and MAPK Pathways (51 papers), Brain Metastases and Treatment (38 papers), Immunotherapy and Immune Responses (25 papers), Cutaneous Melanoma Detection and Management (20 papers), Glioma Diagnosis and Treatment (14 papers) and Lung Cancer Treatments and Mutations (10 papers). The work is most often cited by research in Oncology (3.0k citations), Immunology (1.3k citations) and Pulmonary and Respiratory Medicine (1.4k citations). Hussein A. Tawbi has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include John M. Kirkwood, Ahmad A. Tarhini, F. Stephen Hodi, Cindy Sander, Evan J. Lipson, Michael A. Davies, Kristen N. Ganjoo, Margaret von Mehren, Arthur P. Staddon and Weiyi Peng. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.